Free Trial
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$3.18 +0.04 (+1.27%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$3.20 +0.02 (+0.63%)
As of 09:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Key Stats

Today's Range
$3.12
$3.23
50-Day Range
$3.08
$3.61
52-Week Range
$2.71
$4.73
Volume
544,025 shs
Average Volume
953,212 shs
Market Capitalization
$609.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

ABUS MarketRank™: 

Arbutus Biopharma scored higher than 29% of companies evaluated by MarketBeat, and ranked 779th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arbutus Biopharma has received no research coverage in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arbutus Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.41% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 0.71%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.41% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 0.71%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Arbutus Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus Biopharma Corporation (ABUS) - Yahoo Finance
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $3.27 at the beginning of 2025. Since then, ABUS stock has decreased by 2.8% and is now trading at $3.18.

Arbutus Biopharma Corporation (NASDAQ:ABUS) issued its quarterly earnings results on Wednesday, May, 14th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.54 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 75.51% and a negative net margin of 1,196.64%.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/14/2025
Today
7/09/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABUS
CIK
1447028
Employees
90
Year Founded
1992

Price Target and Rating

High Price Target
$7.00
Low Price Target
$5.00
Potential Upside/Downside
+73.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.92 million
Net Margins
-1,196.64%
Pretax Margin
-1,195.86%

Debt

Sales & Book Value

Annual Sales
$6.17 million
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
6.24

Miscellaneous

Free Float
152,647,000
Market Cap
$609.07 million
Optionable
Optionable
Beta
1.20

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners